Int J Med Sci 2011; 8(3):198-202. doi:10.7150/ijms.8.198 This issue Cite

Research Paper

Antimicrobial Susceptibilities of Brucella Isolates from Various Clinical Speciemens

Yasemin Bayram1, Hanifi Korkoca2, Cenk Aypak3 , Mehmet Parlak4, Aytekin Cikman4, Selcuk Kilic5, Mustafa Berktas4

1. Van Education and Research Hospital, Department of Microbiology, 65100 Van, Turkey.
2. Muş Alparslan University, School of Health, Department of Nursing, 49100 Muş, Turkey.
3. Van Gevaş Hospital, Department of Family Medicine, 65110 Van, Turkey.
4. Van 100. Yil University, Department of Microbiology, 65100 Van, Turkey.
5. Refik Saydam National Hygiene Center, Department of Communicable Diseases Research, 06100 Ankara, Turkey.

Citation:
Bayram Y, Korkoca H, Aypak C, Parlak M, Cikman A, Kilic S, Berktas M. Antimicrobial Susceptibilities of Brucella Isolates from Various Clinical Speciemens. Int J Med Sci 2011; 8(3):198-202. doi:10.7150/ijms.8.198. https://www.medsci.org/v08p0198.htm
Other styles

File import instruction

Abstract

Purpose: Brucellosis is a worldwide zoonotic disease and still constitutes a major public health problem. In the study we claimed to identify Brucella species from clinical samples of patients with active brucellosis from Van region of Eastern Anatolia and to determine in vitro antimicrobial susceptibilities of these strains to commonly used anti-Brucella agents and a possible new alternative tigecycline.

Materials and Methods: A total of 56 Brucella isolates were enrolled the study and the identification of the isolates were based on conventional methods. In vitro activities of antimicrobials were evaluated by the E test method.

Results: All isolates were identified as B. melitensis. MIC90 values of doxycycline, streptomycin, rifampin, trimethoprim-sulfamethoxazole and tigecycline were 0.064 mg/L, 1 mg/L, 2 mg/L, 0.125 mg/L and 0.094 mg/L, respectively. Tigecycline had low MIC50 and MIC90 values against all B. melitensis strains; the highest MIC observed was 0.25 μg/mL.

Conclusion: Our data suggest that tigecycline can be a therapeutic alternative option for the treatment of brucellosis.

Keywords: Brucella, antimicrobial susceptibility, E-test, tigecycline


Citation styles

APA
Bayram, Y., Korkoca, H., Aypak, C., Parlak, M., Cikman, A., Kilic, S., Berktas, M. (2011). Antimicrobial Susceptibilities of Brucella Isolates from Various Clinical Speciemens. International Journal of Medical Sciences, 8(3), 198-202. https://doi.org/10.7150/ijms.8.198.

ACS
Bayram, Y.; Korkoca, H.; Aypak, C.; Parlak, M.; Cikman, A.; Kilic, S.; Berktas, M. Antimicrobial Susceptibilities of Brucella Isolates from Various Clinical Speciemens. Int. J. Med. Sci. 2011, 8 (3), 198-202. DOI: 10.7150/ijms.8.198.

NLM
Bayram Y, Korkoca H, Aypak C, Parlak M, Cikman A, Kilic S, Berktas M. Antimicrobial Susceptibilities of Brucella Isolates from Various Clinical Speciemens. Int J Med Sci 2011; 8(3):198-202. doi:10.7150/ijms.8.198. https://www.medsci.org/v08p0198.htm

CSE
Bayram Y, Korkoca H, Aypak C, Parlak M, Cikman A, Kilic S, Berktas M. 2011. Antimicrobial Susceptibilities of Brucella Isolates from Various Clinical Speciemens. Int J Med Sci. 8(3):198-202.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image